https://diagonaltx.com 2026-03-03T18:10:25.648Z weekly 1 https://diagonaltx.com/legal-documents/privacy-policy 2024-04-02T00:00:00.000Z monthly 0.5 https://diagonaltx.com/legal-documents/terms-of-service 2024-04-02T00:00:00.000Z monthly 0.5 https://diagonaltx.com/news/alk1-bmprii-receptor-clustering-by-an-agonist-bispecific-antibody-rdiag723-prevents-pah-development-in-the-rat-suhx-model 2025-09-29T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-to-present-insights-from-hht-impact-a-natural-history-study-initiated-in-partnership-with-cure-hht-at-ash-2025 2025-12-04T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-to-present-at-the-cure-hhts-15th-international-scientific-conference 2024-10-08T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-to-present-data-at-ash-2024-demonstrating-the-economic-and-clinical-burden-of-hereditary-hemorrhagic-telangiectasia-hht 2024-12-03T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/an-interim-assessment-of-bleeding-events-in-a-prospective-natural-history-study-of-hereditary-hemorrhagic-telangiectasia-patients-using-a-validated-bleeding-scale-and-a-novel-daily-reporting-instrument 2025-12-06T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/ash-2024-characterizing-the-healthcare-resource-utilization-and-costs-of-hereditary-hemorrhagic-telangiectasia 2024-12-07T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-appoints-john-lee-m-d-ph-d-as-chief-medical-officer 2025-07-08T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-announces-publication-of-data-characterizing-the-healthcare-system-cost-and-impact-of-hereditary-hemorrhagic-telangiectasia-hht-in-the-american-journal-of-hematology 2025-07-10T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonals-first-in-class-clustering-antibody-diag723-receives-orphan-drug-designation-odd-from-u-s-fda-and-an-odd-positive-opinion-from-ema-for-treatment-of-hereditary-hemorrhagic-telangiectasia-hht 2025-06-18T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-to-present-new-preclinical-data-demonstrating-disease-modifying-potential-of-receptor-clustering-antibody-approach-in-hht-at-eha-2025-congress 2025-06-12T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-launches-with-128-million-in-financing-to-pioneer-a-new-approach-to-discovering-and-developing-agonist-antibodies-to-tackle-the-underlying-causes-of-severely-debilitating-diseases 2024-04-03T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/15th-hht-international-scientific-conference-bispecific-antibodies-targeting-the-eng-alk1-bmprii-axis-as-a-novel-approach-for-the-treatment-of-hht 2024-10-15T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/the-antibody-series-2024-computational-epitope-filtering-enables-reliable-design-of-agonist-antibodies 2024-09-05T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/eha-2025-alk1-bmprii-receptor-agonism-treats-vascular-pathology-in-hereditary-hemorrhagic-telangiectasia-models 2025-06-14T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-to-present-new-preclinical-data-demonstrating-disease-modifying-potential-of-diag723-in-pulmonary-arterial-hypertension-at-2025-ers-congress 2025-09-29T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/antibody-engineering-therapeutics-europe-2024-il-18r-agonist-bispecific-antibody-with-activity-biased-towards-an-anti-tumor-response 2024-06-05T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-announces-oversubscribed-usd125-million-series-b-financing-to-advance 2026-01-08T00:00:00.000Z monthly 0.7 https://diagonaltx.com/news/diagonal-therapeutics-initiates-natural-history-study-of-adults-living-with-hereditary-hemorrhagic-telangiectasia-hht-a-rare-bleeding-disorder-with-no-approved-treatments 2025-03-04T00:00:00.000Z monthly 0.7